查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1712806

2025年全球放射性药物市场报告

Radiopharmaceuticals Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年放射性药物市场规模将快速成长。预计到 2029 年将成长至 105.9 亿美元，复合年增长率为 11.8%。预测期内的成长是由于老年人口的增加、癌症和心血管疾病盛行率的上升、高额资本投资以及新产品的推出。预测期内的关键趋势包括与其他公司合作以增加收益和提高产品品质、投资扩大工厂产能以满足不断增长的需求、投资新技术以满足新兴需求、探索In Silico模拟以获得更合理和科学的方法、投资人工智慧以降低研发成本并缩短药物开发时间、投资循环系统学技术以增加收益，以及采用特异性疾病的方法以便准确及时诊断癌症。

预计癌症和心血管疾病盛行率的上升将推动放射性药物市场的需求。与传统药物相比，放射性药物正成为一种更安全、更有效的治疗选择，标靶治疗等优势使放射科医师受益于这些疾病的治疗。癌症被公认为全球第二大死因，约占六分之一的死因。例如，2024年4月，总部位于法国的专门机构国际癌症研究机构（IARC）报告称，2022年全球将有约2,000万例新发癌症病例和970万例癌症相关死亡病例。到 2040 年，预计这一数字将上升至每年 2,990 万例新病例和 1,530 万例死亡病例。

由于个人化医疗需求的不断增加，放射性药物市场预计将经历显着增长。个人化医疗，也称为精准医疗，是一种创新的医疗保健方法，根据每个患者的特征来客製化医疗决策、治疗、介入和药物。将个人化医疗融入放射性药物将提高影像和治疗的精确度和准确性，使医疗保健提供者能够提供更有针对性和更有效的治疗。例如，2022年，美国食品药物管理局（FDA）药品评估与研究中心（CDER）核准了37个新分子实体（NME），其中12个（约34%）被个人化医疗联盟（PMC）归类为个人化医疗。因此，个人化医疗需求的不断增长正在推动放射性药物市场的成长。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、新冠疫情、经济復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 世界放射性药物PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球放射性药物市场：成长率分析
  • 全球放射性药物市场表现：规模与成长，2019-2024
  • 全球放射性药物市场预测：2024-2029 年及 2034 年规模与成长
  • 全球放射性药物总目标市场（TAM）

第六章市场区隔

  • 全球放射性药物市场类型、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 诊断
  • 治疗
  • 全球放射性药物市场：依应用、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 肿瘤学
  • 心臟病学
  • 胃肠病学
  • 神经内分泌学
  • 肌肉骨骼
  • 呼吸系统
  • 肾臟病学
  • 其他用途
  • 全球放射性药物市场：按最终用户、绩效和预测，2019-2024 年、2024-2029 年、2034 年
  • 医院及门诊手术中心
  • 诊断中心
  • 癌症研究所
  • 全球放射性药物市场，诊断细分，按类型、绩效和预测，2019-2024 年、2024-2029 年、2034 年
  • 正子断层扫描（PET）放射性药物
  • 单光子发射电脑断层扫描（SPECT）放射性药物
  • 全球放射性药物市场、治疗细分、按类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • α发射体
  • β射线发射器
  • 放射线治疗

第七章 区域和国家分析

  • 全球放射性药物市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球放射性药物市场：依国家、表现及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 放射性药物市场：竞争格局
  • 放射性药物市场：公司简介
    • Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
    • Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • General Electric Company（GE）Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • IBA Group
  • Bayer AG
  • Lantheus Medical Imaging Inc.
  • Bracco Imaging SpA
  • Eckert & Ziegler
  • Nihon Medi-Physics Co. Ltd.
  • Fujifilm Corporation
  • ANSTO
  • Yantai Dongcheng Pharmaceutical Group Co. Ltd.
  • Bracco Imaging SpA.
  • Canon Inc.
  • China Isotope & Radiation Corporation（CIRC）
  • Alliance Medical
  • Advanced Accelerator Applications
  • JSC Isotope

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年放射性药物市场：提供新机会的国家
  • 2029年放射性药物市场：细分市场将带来新机会
  • 2029年放射性药物市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r33021

Radiopharmaceuticals, also known as radioactive medications, are substances used for the diagnosis or treatment of diseases, including cancer, and contain a radioactive material. These medications are employed in various medical procedures to identify specific illnesses or detect medical issues. Patients may receive radiopharmaceuticals through different administration methods, such as injection, oral ingestion, or application into the eye or bladder.

Radiopharmaceuticals can be broadly categorized into diagnostic, therapeutic, and other types. The process of delivering radioactive atoms to targets associated with tumors is known as radiopharmaceutical therapy. These medications find applications in fields such as oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and others. Hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and similar healthcare facilities commonly utilize radiopharmaceuticals for various medical purposes.

The radiopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceuticals market statistics, including radiopharmaceuticals industry global market size, regional shares, competitors with a radiopharmaceuticals market share, detailed radiopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceuticals industry. This radiopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The radiopharmaceuticals market size has grown steadily in recent years. It will grow from $6.46 billion in 2024 to $6.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rise in healthcare expenditure, government initiatives, convenience of treatment, and changes in lifestyles.

The radiopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $10.59 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing geriatric population, increasing prevalence of cancer and cardiovascular diseases, high capital investments, and new product launches. Major trends in the forecast period include collaborating with other companies to boost revenues and improve product quality, investing in plant capacity expansions to cater to the increasing demand, investing in new technologies to meet the emerging demands, explore in silico modeling for a more rational and scientific approach, invest in AI to reduce R&D costs and save drug development time, invest in technologies catering to cardiology to boost revenues and accept disease-specific approaches for accurate and timely diagnosis of cancer.

The rising prevalence of cancer and cardiovascular diseases is expected to drive demand for the radiopharmaceuticals market. Radiopharmaceuticals are becoming a safe and effective therapeutic option compared to conventional medicines, offering advantages such as targeted therapy that benefits radiologists in treating these conditions. Cancer is recognized as the second leading cause of death globally, accounting for approximately 1 in 6 deaths. For instance, in April 2024, the International Agency for Research on Cancer (IARC), a France-based specialized agency, reported that in 2022, nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide. By 2040, these figures are projected to rise to 29.9 million new cases and 15.3 million deaths annually.

The radiopharmaceuticals market is anticipated to experience significant growth, driven by the increasing demand for personalized medicine. Personalized medicine, also known as precision medicine, is an innovative approach to medical care that tailors medical decisions, treatments, interventions, and drug therapies to the unique characteristics of each patient. Integrating personalized medicine into radiopharmaceuticals enhances the precision and accuracy of imaging and therapy, enabling healthcare providers to deliver more targeted and effective care. For example, in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34%, or 12 of them, classified as personalized medicines by the Personalized Medicine Coalition (PMC). The increasing demand for personalized medicine is thus a driving force behind the growth of the radiopharmaceuticals market.

Several companies in the radiopharmaceuticals market are adopting strategic initiatives such as opening new manufacturing facilities and expanding plant capacity, gaining significant popularity. ITM Isotopen Technologien Munchen AG (ITM), for instance, launched a new manufacturing facility in the Munich area to increase the production capacity of high-purity (n.c.a.) Lutetium-177 and no-carrier-added (n.c.a.) Lutetium-177-containing radiopharmaceuticals. This move aims to meet the high demand for quality medical isotopes for precision oncology worldwide.

Major players in the radiopharmaceuticals market are forming partnerships to enhance their market profitability. In June 2023, the University of Pittsburgh Medical Center partnered with PharmaLogic Holdings Corporation to produce new radiopharmaceuticals at a Pittsburgh facility. This collaboration enables patients and professionals in the UPMC vicinity to access innovative diagnostic and therapeutic drugs that are not currently available. The non-exclusive agreement outlines the conversion of experimental radiopharmaceuticals into therapeutically useful medications.

In January 2024, Eli Lilly, a US-based pharmaceutical company, completed its acquisition of Point Biopharma for approximately $1.4 billion. This acquisition aligns with Lilly's strategy to enhance its capabilities in the emerging field of radioligand therapies, which aim to make significant advancements in cancer treatment. Point Biopharma specializes in radiopharmaceuticals, complementing Lilly's existing oncology portfolio and promising to improve patient outcomes. Point Biopharma is a US-based company focused on developing targeted radioligand therapies for various cancers.

Major companies operating in the radiopharmaceuticals market include Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, UJV Rez, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacybapy-Monrol Nuclear Products, NTP Radioisotopes.

North America was the largest region in the global radiopharmaceuticals market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the radiopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The radiopharmaceuticals market consists of sales of technetium disofenin, technetium lidofenin, and technetium mebrofenin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radiopharmaceuticals Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on radiopharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radiopharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The radiopharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Diagnostic, Therapeutic
  • 2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications
  • 3) By End User: Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes
  • Subsegments:
  • 1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals; Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
  • 2) By Therapeutic: Alpha Emitters; Beta Emitters; Brachytherapy
  • Companies Mentioned: Cardinal Health; Curium Pharma; Siemens Healthineers AG; Novartis AG; General Electric Company (GE)
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Radiopharmaceuticals Market Characteristics

3. Radiopharmaceuticals Market Trends And Strategies

4. Radiopharmaceuticals Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Radiopharmaceuticals Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Radiopharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Radiopharmaceuticals Market Growth Rate Analysis
  • 5.4. Global Radiopharmaceuticals Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Radiopharmaceuticals Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Radiopharmaceuticals Total Addressable Market (TAM)

6. Radiopharmaceuticals Market Segmentation

  • 6.1. Global Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Diagnostic
  • Therapeutic
  • 6.2. Global Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Cardiology
  • Gastroenterology
  • Neuroendocrinology
  • Musculoskeletal
  • Respiratory
  • Nephrology
  • Other Applications
  • 6.3. Global Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Ambulatory Surgical Centers
  • Diagnostic Centers
  • Cancer Research Institutes
  • 6.4. Global Radiopharmaceuticals Market, Sub-Segmentation Of Diagnostic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Positron Emission Tomography (PET) Radiopharmaceuticals
  • Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
  • 6.5. Global Radiopharmaceuticals Market, Sub-Segmentation Of Therapeutic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alpha Emitters
  • Beta Emitters
  • Brachytherapy

7. Radiopharmaceuticals Market Regional And Country Analysis

  • 7.1. Global Radiopharmaceuticals Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Radiopharmaceuticals Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Radiopharmaceuticals Market

  • 8.1. Asia-Pacific Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Radiopharmaceuticals Market

  • 9.1. China Radiopharmaceuticals Market Overview
  • 9.2. China Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Radiopharmaceuticals Market

  • 10.1. India Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Radiopharmaceuticals Market

  • 11.1. Japan Radiopharmaceuticals Market Overview
  • 11.2. Japan Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Radiopharmaceuticals Market

  • 12.1. Australia Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Radiopharmaceuticals Market

  • 13.1. Indonesia Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Radiopharmaceuticals Market

  • 14.1. South Korea Radiopharmaceuticals Market Overview
  • 14.2. South Korea Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Radiopharmaceuticals Market

  • 15.1. Western Europe Radiopharmaceuticals Market Overview
  • 15.2. Western Europe Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Radiopharmaceuticals Market

  • 16.1. UK Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Radiopharmaceuticals Market

  • 17.1. Germany Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Radiopharmaceuticals Market

  • 18.1. France Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Radiopharmaceuticals Market

  • 19.1. Italy Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Radiopharmaceuticals Market

  • 20.1. Spain Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Radiopharmaceuticals Market

  • 21.1. Eastern Europe Radiopharmaceuticals Market Overview
  • 21.2. Eastern Europe Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Radiopharmaceuticals Market

  • 22.1. Russia Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Radiopharmaceuticals Market

  • 23.1. North America Radiopharmaceuticals Market Overview
  • 23.2. North America Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Radiopharmaceuticals Market

  • 24.1. USA Radiopharmaceuticals Market Overview
  • 24.2. USA Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Radiopharmaceuticals Market

  • 25.1. Canada Radiopharmaceuticals Market Overview
  • 25.2. Canada Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Radiopharmaceuticals Market

  • 26.1. South America Radiopharmaceuticals Market Overview
  • 26.2. South America Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Radiopharmaceuticals Market

  • 27.1. Brazil Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Radiopharmaceuticals Market

  • 28.1. Middle East Radiopharmaceuticals Market Overview
  • 28.2. Middle East Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Radiopharmaceuticals Market

  • 29.1. Africa Radiopharmaceuticals Market Overview
  • 29.2. Africa Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Radiopharmaceuticals Market Competitive Landscape And Company Profiles

  • 30.1. Radiopharmaceuticals Market Competitive Landscape
  • 30.2. Radiopharmaceuticals Market Company Profiles
    • 30.2.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. General Electric Company (GE) Overview, Products and Services, Strategy and Financial Analysis

31. Radiopharmaceuticals Market Other Major And Innovative Companies

  • 31.1. IBA Group
  • 31.2. Bayer AG
  • 31.3. Lantheus Medical Imaging Inc.
  • 31.4. Bracco Imaging S.p.A.
  • 31.5. Eckert & Ziegler
  • 31.6. Nihon Medi-Physics Co. Ltd.
  • 31.7. Fujifilm Corporation
  • 31.8. ANSTO
  • 31.9. Yantai Dongcheng Pharmaceutical Group Co. Ltd.
  • 31.10. Bracco Imaging SpA.
  • 31.11. Canon Inc.
  • 31.12. China Isotope & Radiation Corporation (CIRC)
  • 31.13. Alliance Medical
  • 31.14. Advanced Accelerator Applications
  • 31.15. JSC Isotope

32. Global Radiopharmaceuticals Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Radiopharmaceuticals Market

34. Recent Developments In The Radiopharmaceuticals Market

35. Radiopharmaceuticals Market High Potential Countries, Segments and Strategies

  • 35.1 Radiopharmaceuticals Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Radiopharmaceuticals Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Radiopharmaceuticals Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer